Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure

Francesco Clemenza, Serge Masson, Pier Giulio Conaldi, Daniele Di Carlo, Alessandro Boccanelli, Gian Francesco Mureddu, Lucio Gonzini, Donata Lucci, Aldo P. Maggioni, Andrea Di Lenarda, Enrico B. Nicolis, Massimo Vanasia, Roberto Latini

Research output: Contribution to journalArticlepeer-review


Background: Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF). Methods and Results: Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints. Conclusions: Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.

Original languageEnglish
Pages (from-to)1543-1546
Number of pages4
JournalCirculation Journal
Issue number10
Publication statusPublished - Sep 25 2017


  • B-type natriuretic peptide
  • Clinical trials
  • Galectin-3
  • Heart failure
  • Mineralocorticoid receptor antagonist

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Galectin-3 and the mineralocorticoid receptor antagonist Canrenone in mild heart failure'. Together they form a unique fingerprint.

Cite this